Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Dexamethasone, Lenalidomide, Carfilzomib, and Daratumumab in Treating Participants with Multiple Myeloma

Multiple Myeloma

This phase II trial studies how well dexamethasone, lenalidomide, carfilzomib, and daratumumab work in treating participants with multiple myeloma. Drugs used in chemotherapy, such as dexamethasone, lenalidomide, and carfilzomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and spread. Giving dexamethasone, lenalidomide, carfilzomib, and daratumumab may work better in treating participants with multiple myeloma.
Multiple Myeloma
II
Dholaria, Bhagirathbhai
NCT03224507
VICCPCL1871

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Either Rituximab or Lenalidomide in Participants With Refractory Large B-Cell Lymphoma

Lymphoma

The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in combination with either rituximab or lenalidomide, as measured by assessment of response rates in adult participants with relapsed / refractory large B-cell lymphoma.
Lymphoma
II
Oluwole, Olalekan
NCT04002401
VICCCTT19106

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: